53
Participants
Start Date
August 26, 2019
Primary Completion Date
June 26, 2024
Study Completion Date
June 26, 2024
HMPL-689
HMPL-689 is a PI3Kδ inhibitor
Clinical Research Alliance, Inc, Westbury
Levine Cancer Institute- Atrium Health, Charlotte
Winship Cancer Institute of Emory University, Atlanta
Tampereen yliopistollinen sairaala, Tampere
CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac
CHU de Nantes - Hotel Dieu, Nantes
Baylor Scott and White Research Institute, Dallas
Renovatio Clinical, Houston
University of Texas Health Science Center at San Antonio, San Antonio
Innovative Clinical Research Institute, Anaheim
Pacific Cancer Medical Center, Anaheim
Ventura County Hematology-Oncology Specialists, Oxnard
Hopital Henri Mondor, Créteil
Medical Oncology Associates, P.S., Spokane
Helsingin yliopistollinen keskussairaala, Helsinki
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna
Ospedale San Raffaele, Milan
KO-MED Centra Kliniczne, Biała Podlaska
Uniwersyteckie Centrum Kliniczne, Gdansk
BioResearch Group Sp. Z. o. o., Krakow
NASZ LEKARZ Osrodek Badan Klinicznych, Torun
ICO Badalona - Hospital Universitari Germans Trias i Pujol, Barcelona
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona
Fundacion Jimenez Diaz, Madrid
Hospital Universitario Virgen del Rocio, Seville
Hospital Universitario Virgen Macarena, Seville
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego, Wroclaw
Lead Sponsor
Hutchmed
INDUSTRY